

*We gratefully acknowledge the support
of our sponsors.*

Gold Sponsor

MaRS Innovation

Silver Sponsors



Bronze Sponsor



bloom burton & co

Technology Transfer Conference
[May 21, 2013]



Network: tbotnew
Username: TBOT
Password: welcome9



bloom burton & co

Welcome to the inaugural Bloom Burton & Co. Technology Transfer Conference 2013!

Bloom Burton exists to *accelerate returns in healthcare* for both innovators and investors.

Our team of medical, scientific, legal, pharmaceutical and capital markets professionals starts with a fundamental approach, driven by a deeper level of diligence, which we combine with our entrepreneurial, creative and tenacious culture to find solutions. We showcase this approach through capital raising and advisory services to companies, publishing research opinions for a broad set of Canadian and international investors and working to support the build-out of the best healthcare companies. This foundation provides us with the tools to make the right monetization events happen.

We believe this event, which showcases the premier pre-venture technologies in Ontario, leverages all of Bloom Burton's strengths, and it brings together inventors, builders, investors and the broader healthcare community.

Thank you for joining us and helping us kick off a week focused on celebrating the health care sector.

Brian & Jolyon

List of Presenters

8:40-9:00	Fluorinov Pharmaceuticals (Company) David O'Neill, PhD	Ontario Institute for Cancer Research
	Fluorinov Pharmaceuticals uses fluorine-based medicinal chemistry to modify specific properties of validated drug candidates to yield new chemical entities. The initial focus areas are oncology and central nervous system disorders.	
9:00-9:20	Vasomune Therapeutics (Company) Parimal Nathwani, MSc, MBA	Mars Innovation
	Vasomune Therapeutics is developing novel agents for the treatment of diseases associated with vascular inflammation and destabilization. Vasomune has developed Vasculotide, a peptide that activates the Tie2 receptor and may be important in treating acute kidney injury and acute lung injury.	
9:20-9:40	Encycle Therapeutics (Company) Jeffrey Coull, PhD	Mars Innovation
	Encycle Therapeutics has developed a strategy to produce novel macrocycles useful for examining protein interactions that were previously very difficult to study. This discovery is important for understanding protein-protein interactions and for identifying new drug targets.	
9:40-10:00	ScaRX (Company) Ivan Waissbluth, PhD	Mars Innovation
	ScarX is a topical skin cream that contains the nefopam molecule, which targets scar tissue-producing myofibroblast cells. This skin cream effectively reduces scarring when applied directly to a surgical wound.	
10:00-10:20	DLVR Therapeutics (Company) Frank Gleeson, MBA	Mars Innovation
	DLVR has developed a nanoparticle called HPPS (HDL-like Peptide-Phospholipid Scaffold) that utilizes the properties of high-density lipoproteins to create a hydrophobic channel in cell membranes. By creating a pore in the cell membrane HPPS can deliver drugs directly to the interior of a cell, an important tool for drug delivery, particularly chemotherapeutics.	
10:20-10:40	InDanio BioSciences (Company) Prakash Gowd, MBA	Ontario Centres of Excellence
	InDanio Biosciences has developed a "ligand-trap" system that uses live zebrafish to identify small molecules that target nuclear receptor proteins. Diseases controlled by hormones and drugs that act on nuclear receptor proteins are very widespread; this system allows for simpler identification and isolation of entities that act on nuclear receptor proteins, greatly streamlining the drug discovery process.	

10:40-11:00 **Kapplex Inc. (Company)** **MaRS Innovation**
Jean-Francois Houle

Kapplex is developing leading-edge instruments and consumables for the life sciences, pharmaceutical drug discovery and diagnostic markets. Kapplex products are powered by a proprietary Digital MicroFluidic (DMF) platform that automates traditional biochemical and cellular sample preparations, separations and analyses on a single, low-cost chip.

11:00-11:30 **Hon. Gary Goodyear, Minister of State (Science & Technology),**
announces new Genome Canada funding program.

11:30-11:50 **Cellax (Company)** **Ontario Institute for**
Mark Ernstring, PhD **Cancer Research**

Cellax is a nanoparticle drug delivery system that improves the targeting of the chemotherapeutic docetaxel to cancer cells. This delivery system increases drug efficacy, and reduces adverse toxicity associated with chemotherapy.

11:50-12:10 **Insulin Induced Hypoglycemia (Technology)** **MaRS Innovation**
Michael Riddell, PhD

Inhibition of somatostatin receptor type 2 in the alpha cells of the pancreas prevents insulin induced hypoglycemia, the lead complication on all insulin labels. Development of pharmacological antagonists for this receptor could prove important for the treatment of insulin induced hypoglycemia.

12:10-13:30 **Lunch Panel: Investor Outlook for Early Stage Companies**

Moderator:
Armand Balboni, Bloom Burton & Co.

Panelists:
Ela Borenstein, BDC Capital
Vikas Goyal, SR One
Parimal Nathwani, MaRS Innovation
Scott Weiner, Pappas Ventures

13:30-13:50 **Brown Adipose Tissue Modulation (Tech.)** **Centre for Comm. Of**
Michael May, PhD **Regen. Med.**

Researchers affiliated with CCRM are developing an approach that will reduce brown adipose tissue in vivo, leading to reduction in weight, and to improve insulin sensitivity and glucose control. CCRM is focused on supporting the advancement of this technology, which will be important for the treatment of obesity and type 2 diabetes.

13:50-14:10 **Harmonic Medical (Company)** **Ontario Institute for**
Fred Francis **Cancer Research**

Harmonic Medical researches, develops, manufactures and markets the first and only focused ultrasound therapeutic medical device platform with self-contained diagnostic ultrasound ablation precision monitoring. This is achieved using its proprietary local harmonic motion measurement technology which is the culmination of 15 years of research by Harmonic's founder Dr. Kullervo Hynynen at Harvard's Brigham and Women's Hospital and at the Sunnybrook Health Sciences Centre. The first two applications of Harmonic's therapeutic platform currently being developed are OncoPAL™ for pain relief ablation of bone cancer metastasis and Marlei™ for management ablation of uterine fibroids.

14:10-14:30 **Less Costly and Portable PET (Technology)** **Ontario Brain**
Sasha Bubon, MSc **Institute**

Sasha Bubon, an entrepreneur supported by the OBI working at the Thunder Bay Regional Research Institute, is revolutionizing PET technologies so that they are easily transportable. This will make it possible for patients to be scanned in their home, particularly beneficial for people suffering from Alzheimer's disease, cancer, and those living in remote areas.

14:30-14:50 **Eve Medical (Company)** **Ontario Centres of**
Evan Moses **Excellence**

Eve Medical is developing a personal use technology that makes it easier for women to collect their own samples for HPV, Chlamydia, and Gonorrhea screening. Simplifying the screening process in this way will prevent under-screening and make the detection process for cervical cancer and STI's more efficacious.

14:50-15:10 Decellularized Adipose Tissue (Technology) Ontario Centres of Excellence
Jason Hendry, MAsc

Decellularized adipose tissue is a scaffold created from human fat that can be implanted in to the human body during reconstructive surgery to stimulate the growth of soft tissues. Following implantation normal tissue growth occurs, meaning this process could simplify reconstructive procedures and generate more desirable surgical outcomes.

15:10-15:30 Therapeutic to lower VLDL and LDL McMaster University
Shirya Rashid PhD

Inhibition of resistin lowers blood VLDL and LDL levels by increasing liver LDL receptor expression. This technology can be used to potentially reduce premature development of cardiovascular diseases, including heart attacks in obese individuals.

15:30-15:50 Avenir Medical Inc
Armen Bakirtzian

Avenir Medical is an early-stage medical device company focusing on improving patient outcomes in joint replacement surgery. Avenir is the creator of PelvAssist™, a novel intelligent instrument that helps surgeons place implant properly in the body to avoid painful complications.

15:50-16:10 Inceptum Research & Therapeutics
Armen Manoukian, PhD


Unique in vivo platform and approach has allowed Inceptum Research & Therapeutics to identify and validate kinase regulators for clinical development. One such screen for inhibitors of Glycogen Synthase Kinase 3 has identified multiple drug classes, novel genetic targets along with valuable biomarkers for clinical development validating the superiority of the phenotypic chemical genetic approach to drug discovery.

16:10-16:30 Translatum Medicus
Shelley Boyd, MD


Translatum Medicus Inc (TMI) is dedicated to bringing new therapies for the treatment of Age Related Macular Degeneration (AMD) – the leading cause of blindness in the western world -- to market via the shortest path. Through development of the only animal model to mimic the blinding complications of advanced so-called "dry" AMD, alignment of pre-clinical markers with FDA-approved endpoints, local clinical trial facilities, and a dedicated AMD clinic focused on a high-risk patient population, TMI offers an unprecedented and focused conduit for translating new science into medicine.

Select Transactions:

M&A Transaction
Approx. \$510,000,000



GILEAD
 completes acquisition of



YM BIOSCIENCES INC.

December 2012
 Advisor to YM BioSciences

Private Placement
US\$12,500,000



Units
 December 2012

Venture Debt
\$7,500,000



TRIMEL
 UKPHARMA

July 2012

Secured Debt
\$8,000,000



issues debt to



NUVO

May 2012
 Advisor to Nuvo

Public Offering
\$3,100,000



STEM CELL
THERAPEUTICS

Units
 March 2013

Overnight Offering
\$2,550,000



Common Share Units
 July 2012


Fairness Opinion



WARNEX

October 2012
 Advisor

Public Offering
US\$80,500,000



YM BIOSCIENCES INC.

Common Shares
 February 2012

We gratefully acknowledge the support of our sponsors.

Gold Sponsors



Heenan Blaikie



Silver Sponsor



bloom burton & co

Healthcare Investor Conference
[May 22, 2013]



Network: tbotnew
Username: TBOT
Password: welcome9

Corporate presentations will be available via a weblink to be emailed to attendees after the conference.



bloom burton & co

Welcome to the 2013 Bloom Burton & Co. Healthcare Investor Conference!


Bloom Burton exists to *accelerate returns in healthcare* for both companies and investors.

Our team of medical, scientific, legal, pharmaceutical and capital markets professionals start with a fundamental approach, driven by a deeper level of diligence, which we combine with our entrepreneurial, creative and tenacious culture to find solutions. We showcase this approach through capital raising and advisory services to companies, publishing research opinions for a broad set of Canadian and international investors and working to support the build-out of the best healthcare companies. This foundation provides us with the tools to make the right monetization events happen.

We believe our Healthcare Investor Conference brings together all of these qualities, and it brings together all of you, our valued partners and clients, to meet and plan the success of the healthcare sector in Canada.

Thank you for joining us!

Brian & Jolyon





bloom burton & co

Healthcare Investor Conference

8:00 Continental Breakfast - *Main Ballroom*

Welcome and Introductory Remarks - *Main Ballroom*

8:30-9:30

Speaker: Jolyon Burton, CEO & Head of Investment Banking, Bloom Burton & Co.

Keynote Speech - *Main Ballroom*

Speaker: John Johnston, Ph.D., Chief Strategist, Davis Rea Ltd.

30-minute Company Presentations

Room A/B

Room C/D

Lounge

9:30	Oncolytics Biotech	Pharmascience	STI Technologies
10:00	OncoGenex Pharmaceuticals	Merus Labs	Agility Health
10:30	Æterna Zentaris	Trimel Pharmaceuticals	Xenon Pharmaceuticals
11:00	CML Healthcare	Paladin Labs	Zymeworks
11:30	Resverlogix	Cipher Pharmaceuticals	Aquinox

12:00-1:30

Lunch & Discussion - *Main Ballroom*

Buyside Investors Panel: How Healthcare Companies Can Attract Buyside Interest

30-minute Company Presentations

Room A/B

Room C/D

Lounge

1:30	Cardiome Pharma	Nuvo Research	Jennerex
2:00	Centric Health	Tribute Pharmaceuticals	iCo Therapeutics
2:30	GeneNews	Medicago	Diamedica
3:00	CRH Medical	Transition Therapeutics	Induce Biologics
3:30	Tekmira Pharmaceuticals	ProMetic Life Sciences	Response Biomedical
4:00	Bellus Health	Bioniche Life Sciences	biOasis Technologies

One-on-One Meetings on Third Floor




Heenan Blaikie



Toronto Stock Exchange

TSX Venture Exchange

Select Transactions:



M&A Transaction
Approx. \$510,000,000



completes acquisition of



December 2012
Advisor to YM BioSciences

Private Placement
US\$12,500,000



Units
December 2012

Venture Debt
\$7,500,000



July 2012

Secured Debt
\$8,000,000



issues debt to



May 2012
Advisor to Nuvo

Public Offering
\$3,100,000



Units
March 2013

Overnight Offering
\$2,550,000




Common Share Units
July 2012

Fairness Opinion



October 2012
Advisor

Public Offering
US\$80,500,000



Common Shares
February 2012